Experimental drug aims to rebuild immune defenses in rare disease
NCT ID NCT05600920
First seen Jan 08, 2026 · Last updated May 07, 2026 · Updated 19 times
Summary
This study tests a new drug called NT-I7 in people with idiopathic CD4 lymphopenia (ICL), a rare condition where the body lacks key immune cells called CD4 T cells. The goal is to see if NT-I7 can safely increase these cells and help prevent severe infections. About 60 adults aged 18 to 75 will receive three injections over several months, with close monitoring for side effects and immune changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.